Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
WALTHAM, Mass., July 18, 2017 -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that the Compensation Committee of the Company’s Board of Directors granted Jesper Høiland, the Company’s President and Chief Executive Officer, an option to purchase 305,000 shares of the Company’s common stock with a per share exercise price of $42.97, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of July 17, 2017. The option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock option was granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce Mr. Høiland to enter into employment with the Company.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius’ lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius’ RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825
